Login to Your Account



UCB Reports Positive Early Data on Cimzia in Crohn's Disease

By Donna Young


Wednesday, March 5, 2008
Six-week data from a 539-patient Phase IIIb trial showed that UCB SA's Cimzia, a PEGylated antitumor-necrosis-factor (TNF)-alpha product, was effective in treating patients with Crohn's disease who are intolerant or no longer responding to infliximab. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription